Meta AnalysisID 7250
α-硫辛酸治疗糖尿病神经病变的疗效评估：一项全面的系统评价
CRD42023453457
PICO: Population (P): Patients with diabetic neuropathy Intervention (I): Treatment with Alpha-Lipoic Acid Comparison (C): Standard treatment without Alpha-Lipoic Acid or Placebo Outcome (O): Improvement in neuropathic s
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7250
- Evidence Id
- 15808
- Core Evidence Id
- 15808
- Source Meta Analysis Id
- 7234
- Herb2 Meta Analysis Id
- HBMA007234
- Crd Id
- CRD42023453457
- Title
- Assessing the Efficacy of Alpha-Lipoic Acid in Managing Diabetic Neuropathy: A Comprehensive Systematic Review
- Review Question
- PICO: Population (P): Patients with diabetic neuropathy Intervention (I): Treatment with Alpha-Lipoic Acid Comparison (C): Standard treatment without Alpha-Lipoic Acid or Placebo Outcome (O): Improvement in neuropathic symptoms, disease progression, quality of life, and any adverse effects
- Study Type Included
- This systematic review will encompass various study designs to comprehensively assess the efficacy of Alpha-Lipoic Acid (ALA) in managing diabetic neuropathy. The review will include randomized controlled trials (RCTs) that offer robust evidence on ALA's impact. Non-randomized comparative studies, such as cohort and case-control studies, will be considered to evaluate treatment effects in real-world contexts. Longitudinal and prospective observational studies will provide insights into the long-term effects of ALA on neuropathic symptoms and disease progression. Additionally, case reports and case series will be included to report adverse effects and rare outcomes associated with ALA treatment. By incorporating a diverse range of study designs, this systematic review aims to comprehensively inform the potential therapeutic benefits of ALA in addressing diabetic neuropathy.
- Condition Being Studied
- The focus of this systematic review is to assess the effect of alpha-lipoic acid in the treatment of diabetic neuropathy. Diabetic neuropathy refers to nerve damage arising from prolonged hyperglycemia in individuals with diabetes mellitus, leading to a range of sensory, motor, and autonomic symptoms. This review aims to analyze the potential therapeutic role of alpha-lipoic acid in alleviating neuropathic symptoms and its implications for managing diabetic neuropathy.
- Participant
- This systematic review focuses on individuals with diabetic neuropathy, a prevalent complication of diabetes mellitus. Diabetic neuropathy is characterized by nerve damage leading to various distressing symptoms, such as pain, tingling, numbness, and impaired sensory functions. The target population for this review includes individuals of diverse demographics who have been diagnosed with diabetic neuropathy, regardless of age, gender, or ethnicity. Participants may have varying degrees of neuropathic symptoms, encompassing sensory, motor, or autonomic manifestations. Studies involving patients with type 1 or type 2 diabetes will be considered, as long as they meet the diagnostic criteria for diabetic neuropathy. The review will encompass a range of study designs, including randomized controlled trials, observational studies, and case series, to comprehensively evaluate the efficacy of Alpha-Lipoic Acid in managing diabetic neuropathy. By synthesizing data from a diverse population, this review aims to provide valuable insights into the potential benefits of Alpha-Lipoic Acid for individuals suffering from diabetic neuropathy.
- Animal
- Human Disease Modelled
- Intervention
- The intervention under investigation is the use of Alpha-Lipoic Acid (ALA) as a therapeutic approach for managing diabetic neuropathy. Diabetic neuropathy is a common complication of diabetes mellitus characterized by nerve damage and debilitating symptoms. ALA, a naturally occurring antioxidant, has gained attention for its potential to mitigate neuropathic symptoms and improve the overall quality of life in affected individuals. The intervention involves administering Alpha-Lipoic Acid orally or through other appropriate routes, with the aim of evaluating its efficacy in alleviating neuropathic pain, enhancing sensory functions, and potentially slowing disease progression. The treatment will be compared against standard management approaches without Alpha-Lipoic Acid or placebo. This systematic review aims to comprehensively assess the existing evidence on the effectiveness of Alpha-Lipoic Acid as a therapeutic intervention for diabetic neuropathy. The review will encompass a rigorous analysis of preclinical and clinical studies, examining outcomes such as symptom improvement, disease progression, quality of life, and adverse effects.
- Comparator Control
- The comparison group in this systematic review comprises individuals receiving standard treatment without Alpha-Lipoic Acid (ALA) or placebo. This group reflects the conventional therapeutic approach for diabetic neuropathy management, enabling a comprehensive evaluation of ALA's efficacy in comparison to established treatments. The control group's outcomes will be contrasted with those of the intervention group receiving ALA to determine the relative impact of the intervention on neuropathic symptoms, disease progression, quality of life, and adverse effects. This comparison is vital for elucidating the potential benefits and limitations of ALA as a therapeutic option for diabetic neuropathy. By examining both intervention and control groups, this review aims to provide a thorough understanding of ALA's effects and contribute to evidence-based recommendations for clinical practice.
- Main Outcome
- The primary outcomes of interest for this systematic review are the improvement in neuropathic symptoms, disease progression, quality of life, and any adverse effects associated with the use of Alpha-Lipoic Acid (ALA) in managing diabetic neuropathy. The review will focus on assessing the impact of ALA on alleviating sensory, motor, and autonomic symptoms of diabetic neuropathy, as well as its potential to slow down or halt the progression of nerve damage. Additionally, the review will examine the influence of ALA on the overall quality of life of individuals with diabetic neuropathy, considering both physical and psychosocial well-being. Adverse effects, if reported, will be carefully analyzed to evaluate the safety profile of ALA treatment. By systematically examining these main outcomes, this review aims to provide a comprehensive understanding of the potential benefits and risks associated with ALA as a therapeutic intervention for diabetic neuropathy.
- Outcome Measure
- Additional Outcome
- Study Method
- Systematic review
- Keyword
- Diabetes Mellitus; Diabetic Neuropathies; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Patients; Quality of Life; Thioctic Acid
- Contact
- Samiah Bahkali [email protected]
- Organisational Affiliation
- King Abdulaziz University Hospital
- Funding Source
- No funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Saudi Arabia
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-08-15
- Registration Date
- 2023-08-26
- Anticipated Start Date
- 2023-08-08
- Anticipated Completion Date
- 2023-09-17
- Title Cn
- α-硫辛酸治疗糖尿病神经病变的疗效评估：一项全面的系统评价
- Title En
- Assessing the Efficacy of Alpha-Lipoic Acid in Managing Diabetic Neuropathy: A Comprehensive Systematic Review
- Bilingual Status
- complete